Axon Enterprise, Inc. (NASDAQ:AXON) Shares Sold by Ulland Investment Advisors LLC

Ulland Investment Advisors LLC lessened its holdings in Axon Enterprise, Inc. (NASDAQ:AXON) by 1.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 21,818 shares of the biotechnology company’s stock after selling 317 shares during the quarter. Axon Enterprise comprises approximately 6.4% of Ulland Investment Advisors LLC’s investment portfolio, making the stock its 3rd largest holding. Ulland Investment Advisors LLC’s holdings in Axon Enterprise were worth $8,718,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Quent Capital LLC boosted its stake in shares of Axon Enterprise by 1,875.0% in the third quarter. Quent Capital LLC now owns 79 shares of the biotechnology company’s stock worth $32,000 after buying an additional 75 shares during the last quarter. Blue Trust Inc. lifted its holdings in Axon Enterprise by 987.5% in the second quarter. Blue Trust Inc. now owns 87 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 79 shares during the period. Trivant Custom Portfolio Group LLC purchased a new stake in Axon Enterprise in the 1st quarter worth approximately $31,000. First PREMIER Bank purchased a new stake in Axon Enterprise in the 1st quarter worth approximately $33,000. Finally, Rise Advisors LLC grew its stake in shares of Axon Enterprise by 49.0% during the 1st quarter. Rise Advisors LLC now owns 143 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 47 shares during the period. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Axon Enterprise

In related news, CEO Patrick W. Smith sold 4,767 shares of Axon Enterprise stock in a transaction that occurred on Thursday, October 3rd. The shares were sold at an average price of $404.14, for a total value of $1,926,535.38. Following the completion of the sale, the chief executive officer now owns 2,925,060 shares in the company, valued at approximately $1,182,133,748.40. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO Patrick W. Smith sold 47,314 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $400.07, for a total transaction of $18,928,911.98. Following the sale, the chief executive officer now directly owns 2,983,802 shares of the company’s stock, valued at $1,193,729,666.14. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Patrick W. Smith sold 4,767 shares of the firm’s stock in a transaction that occurred on Thursday, October 3rd. The shares were sold at an average price of $404.14, for a total transaction of $1,926,535.38. Following the completion of the transaction, the chief executive officer now directly owns 2,925,060 shares of the company’s stock, valued at $1,182,133,748.40. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 370,172 shares of company stock valued at $136,562,182 over the last 90 days. 6.10% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on AXON shares. Needham & Company LLC reiterated a “buy” rating and issued a $400.00 price objective on shares of Axon Enterprise in a research report on Wednesday, August 7th. Jefferies Financial Group began coverage on Axon Enterprise in a research report on Wednesday, July 17th. They set a “buy” rating and a $385.00 price target on the stock. Bank of America assumed coverage on Axon Enterprise in a research report on Wednesday, July 17th. They issued a “buy” rating and a $380.00 price objective for the company. Northland Securities upped their target price on Axon Enterprise from $330.00 to $365.00 and gave the stock an “outperform” rating in a research note on Thursday, August 8th. Finally, Robert W. Baird lifted their price target on shares of Axon Enterprise from $360.00 to $400.00 and gave the company an “outperform” rating in a research note on Tuesday, September 10th. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $365.38.

Axon Enterprise Price Performance

AXON stock traded down $7.36 during mid-day trading on Tuesday, reaching $430.62. The company’s stock had a trading volume of 225,867 shares, compared to its average volume of 522,619. The company’s 50 day moving average is $381.46 and its two-hundred day moving average is $328.45. The stock has a market cap of $32.54 billion, a PE ratio of 115.56, a P/E/G ratio of 11.49 and a beta of 0.94. The company has a current ratio of 2.88, a quick ratio of 2.52 and a debt-to-equity ratio of 0.35. Axon Enterprise, Inc. has a fifty-two week low of $199.29 and a fifty-two week high of $440.89.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.18. The business had revenue of $504.00 million during the quarter, compared to the consensus estimate of $478.35 million. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The business’s revenue was up 34.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.80 EPS. Equities research analysts expect that Axon Enterprise, Inc. will post 1.79 EPS for the current year.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.